Pharma BD Deal Intelligence

Valeant Pharmaceuticals International Inc. / Bausch + Lomb

2013 · Acquisition/Merger · $8.7B · Complete

Announcement Sentiment

Strongly positive

Valeant agreed to acquire Bausch + Lomb from Warburg Pincus-led group for $8.7B cash ($4.5B to investors, $4.2B to repay B+L debt); created global eye-health platform with pro-forma 2013 net revenue >$3.5B.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced May 27, 2013
Closed Aug 05, 2013
Deal value $8.7B
Deal type Acquisition/Merger
Therapeutic area Ophthalmology
Indications Ophthalmology
Key assets Eye health portfolio (contacts, ophthalmic Rx, surgical, OTC)
Mechanism Mixed eye-health portfolio (lubricants, glaucoma, surgical products)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals